Corticosteroids for COVID-19

作     者：Djillali Annane 

作者机构：Department of Intensive CareHôpital Raymond Poincare(APHP)Laboratory of Infection&Inflammation-U1173School of Medicine Simone VeilUniversity Versailles Saint Quentin-University Paris SaclayINSERM104 boulevard Raymond PoincareGarches 92380France 

出 版 物：《Journal of Intensive Medicine》 (重症医学（英文）)

年 卷 期：2021年第1卷第1期

页      面：14-25页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Coronavirus Corticosteroids Inflammatory mediators Trials Survival Superinfections 

摘      要：Coronavirus disease 19(COVID-19)is placing a major burden on healthcare,economy and social systems world-wide owing to its fast spread and unacceptably high death *** unprecedented research effort has established the role of a deregulated immune response to the severe acute respiratory syndrome coronavirus 2,resulting in systemic *** that,the immunomodulatory approach has been placed in the top list of the re-search agenda for *** have been used for more than 70 years to modulate the immune response in a broad variety of *** drugs have been shown to prevent and attenuate inflammation both in tissues and in circulation via non-genomic and genomic *** the bedside,numerous observational cohorts have been published in the past months and have been *** controlled trials with subsequent high quality meta-analyses have provided moderate to strong certainty for an increased chance of survival and relief from life supportive therapy with corticosteroids given at a dose of 6 mg per day dexametha-sone or equivalent doses of hydrocortisone or *** corticotherapy was not associated with an increased risk of bacterial infection or of delayed viral *** daily practice,physicians may be encouraged to use corticosteroids when managing patients with COVID-19 requiring oxygen supplementation.